Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Roles of Fc domain and exudation in L2 antibody-mediated protection against human papillomavirus.

Wang JW, Wu WH, Huang TC, Wong M, Kwak K, Ozato K, Hung CF, Roden RBS.

J Virol. 2018 May 9. pii: JVI.00572-18. doi: 10.1128/JVI.00572-18. [Epub ahead of print]

PMID:
29743371
2.

Opportunities and challenges for human papillomavirus vaccination in cancer.

Roden RBS, Stern PL.

Nat Rev Cancer. 2018 Apr;18(4):240-254. doi: 10.1038/nrc.2018.13. Epub 2018 Mar 2. Review.

PMID:
29497146
3.

The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.

Ahn J, Bishop JA, Roden RBS, Allen CT, Best SRA.

Laryngoscope. 2018 Jan;128(1):E27-E32. doi: 10.1002/lary.26847. Epub 2017 Sep 22.

PMID:
28940446
4.

Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice.

Ahn J, Peng S, Hung CF, Roden RBS, Best SR.

Laryngoscope. 2018 Jan;128(1):E16-E20. doi: 10.1002/lary.26772. Epub 2017 Sep 4.

PMID:
28868617
5.

Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.

Jiang RT, Yemelyanova A, Xing D, Anchoori RK, Hamazaki J, Murata S, Seidman JD, Wang TL, Roden RBS.

J Ovarian Res. 2017 Aug 7;10(1):53. doi: 10.1186/s13048-017-0347-y.

6.

Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.

Kalnin K, Chivukula S, Tibbitts T, Yan Y, Stegalkina S, Shen L, Cieszynski J, Costa V, Sabharwal R, Anderson SF, Christensen N, Jagu S, Roden RBS, Kleanthous H.

Vaccine. 2017 Sep 5;35(37):4942-4951. doi: 10.1016/j.vaccine.2017.07.086. Epub 2017 Aug 1.

7.

Immunologic responses to a novel DNA vaccine targeting human papillomavirus-11 E6E7.

Ahn J, Peng S, Hung CF, Roden RBS, Wu TC, Best SR.

Laryngoscope. 2017 Dec;127(12):2713-2720. doi: 10.1002/lary.26737. Epub 2017 Jul 17.

PMID:
28714529
8.

Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease.

Shah AA, Rosen A, Hummers LK, May BJ, Kaushiva A, Roden RBS, Armstrong DK, Wigley FM, Casciola-Rosen L, Visvanathan K.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):71-74. Epub 2017 Jun 19.

9.

Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.

Jiang RT, Wang JW, Peng S, Huang TC, Wang C, Cannella F, Chang YN, Viscidi RP, Best SRA, Hung CF, Roden RBS.

J Virol. 2017 Jul 12;91(15). pii: e00699-17. doi: 10.1128/JVI.00699-17. Print 2017 Aug 1.

10.

An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors.

Li QK, Shah P, Tian Y, Hu Y, Roden RBS, Zhang H, Chan DW.

Clin Proteomics. 2017 May 10;14:16. doi: 10.1186/s12014-017-9152-2. eCollection 2017.

11.

Developments in L2-based human papillomavirus (HPV) vaccines.

Schellenbacher C, Roden RBS, Kirnbauer R.

Virus Res. 2017 Mar 2;231:166-175. doi: 10.1016/j.virusres.2016.11.020. Epub 2016 Nov 23. Review.

12.

RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.

Soong RS, Anchoori RK, Yang B, Yang A, Tseng SH, He L, Tsai YC, Roden RB, Hung CF.

Oncotarget. 2016 Oct 18;7(42):68489-68502. doi: 10.18632/oncotarget.12095.

13.

Immunizing against Anogenital Cancer: HPV Vaccines.

Pogoda CS, Roden RB, Garcea RL.

PLoS Pathog. 2016 May 19;12(5):e1005587. doi: 10.1371/journal.ppat.1005587. eCollection 2016 May. Review. No abstract available.

14.

Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.

Peng S, Qiu J, Yang A, Yang B, Jeang J, Wang JW, Chang YN, Brayton C, Roden RBS, Hung CF, Wu TC.

Cell Biosci. 2016 Feb 25;6:16. doi: 10.1186/s13578-016-0080-z. eCollection 2016.

15.

The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression.

Randles L, Anchoori RK, Roden RB, Walters KJ.

J Biol Chem. 2016 Apr 15;291(16):8773-83. doi: 10.1074/jbc.M115.694588. Epub 2016 Feb 23.

16.

Progress and prospects for L2-based human papillomavirus vaccines.

Jiang RT, Schellenbacher C, Chackerian B, Roden RB.

Expert Rev Vaccines. 2016 Jul;15(7):853-62. doi: 10.1586/14760584.2016.1157479. Epub 2016 Mar 10. Review.

17.

Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence-Coupled Biopanning Platform.

Frietze KM, Roden RB, Lee JH, Shi Y, Peabody DS, Chackerian B.

Cancer Immunol Res. 2016 Feb;4(2):157-64. doi: 10.1158/2326-6066.CIR-15-0165. Epub 2015 Nov 20.

18.

Immunologic Control of Mus musculus Papillomavirus Type 1.

Wang JW, Jiang R, Peng S, Chang YN, Hung CF, Roden RB.

PLoS Pathog. 2015 Oct 23;11(10):e1005243. doi: 10.1371/journal.ppat.1005243. eCollection 2015 Oct.

19.

Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.

Sun YY, Peng S, Han L, Qiu J, Song L, Tsai Y, Yang B, Roden RB, Trimble CL, Hung CF, Wu TC.

Clin Cancer Res. 2016 Feb 1;22(3):657-69. doi: 10.1158/1078-0432.CCR-15-0234. Epub 2015 Sep 29.

20.

Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.

Jagu S, Karanam B, Wang JW, Zayed H, Weghofer M, Brendle SA, Balogh KK, Tossi KP, Roden RBS, Christensen ND.

Vaccine. 2015 Oct 13;33(42):5553-5563. doi: 10.1016/j.vaccine.2015.09.005. Epub 2015 Sep 15.

21.

Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.

Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA.

Virol J. 2015 Sep 11;12:140. doi: 10.1186/s12985-015-0364-7.

22.

Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies.

Wang JW, Matsui K, Pan Y, Kwak K, Peng S, Kemp T, Pinto L, Roden RB.

Curr Protoc Microbiol. 2015 Aug 3;38:14B.5.1-26. doi: 10.1002/9780471729259.mc14b05s38.

23.

Weight change in breast cancer survivors compared to cancer-free women: a prospective study in women at familial risk of breast cancer.

Gross AL, May BJ, Axilbund JE, Armstrong DK, Roden RB, Visvanathan K.

Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1262-9. doi: 10.1158/1055-9965.EPI-15-0212. Epub 2015 Jul 15.

24.

Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination.

Yang B, Yang A, Peng S, Pang X, Roden RB, Wu TC, Hung CF.

Cell Biosci. 2015 Jun 25;5:35. doi: 10.1186/s13578-015-0025-y. eCollection 2015.

25.

Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Wang JW, Jagu S, Wu WH, Viscidi RP, Macgregor-Das A, Fogel JM, Kwak K, Daayana S, Kitchener H, Stern PL, Gravitt PE, Trimble CL, Roden RB.

Clin Vaccine Immunol. 2015 Jul;22(7):806-16. doi: 10.1128/CVI.00799-14. Epub 2015 May 13.

26.

Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells.

Vogel RI, Coughlin K, Scotti A, Iizuka Y, Anchoori R, Roden RB, Marastoni M, Bazzaro M.

Oncotarget. 2015 Feb 28;6(6):4159-70.

27.

Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer.

Peng S, Wang JW, Karanam B, Wang C, Huh WK, Alvarez RD, Pai SI, Hung CF, Wu TC, Roden RB.

PLoS One. 2015 Jan 5;10(1):e116389. doi: 10.1371/journal.pone.0116389. eCollection 2015.

28.

Immunoprevention of human papillomavirus-associated malignancies.

Wang JW, Hung CF, Huh WK, Trimble CL, Roden RB.

Cancer Prev Res (Phila). 2015 Feb;8(2):95-104. doi: 10.1158/1940-6207.CAPR-14-0311. Epub 2014 Dec 8. Review.

29.

Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.

Erickson BK, Kinde I, Dobbin ZC, Wang Y, Martin JY, Alvarez RD, Conner MG, Huh WK, Roden RB, Kinzler KW, Papadopoulos N, Vogelstein B, Diaz LA Jr, Landen CN Jr.

Obstet Gynecol. 2014 Nov;124(5):881-5. doi: 10.1097/AOG.0000000000000484.

30.

GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility.

Banet N, Gown AM, Shih IeM, Kay Li Q, Roden RB, Nucci MR, Cheng L, Przybycin CG, Nasseri-Nik N, Wu LS, Netto GJ, Ronnett BM, Vang R.

Am J Surg Pathol. 2015 Jan;39(1):101-8. doi: 10.1097/PAS.0000000000000315.

31.

Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.

Wang JW, Jagu S, Wang C, Kitchener HC, Daayana S, Stern PL, Pang S, Day PM, Huh WK, Roden RB.

PLoS One. 2014 Jul 7;9(7):e101576. doi: 10.1371/journal.pone.0101576. eCollection 2014.

32.

Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.

Berg MG, Adams RJ, Gambhira R, Siracusa MC, Scott AL, Roden RB, Ketner G.

Clin Vaccine Immunol. 2014 Sep;21(9):1224-31. doi: 10.1128/CVI.00197-14. Epub 2014 Jul 2.

33.

Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFN╬│.

Soong RS, Song L, Trieu J, Knoff J, He L, Tsai YC, Huh W, Chang YN, Cheng WF, Roden RB, Wu TC, Trimble CL, Hung CF.

Clin Cancer Res. 2014 Nov 1;20(21):5456-67. doi: 10.1158/1078-0432.CCR-14-0344. Epub 2014 Jun 3.

34.

Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.

Kwak K, Jiang R, Wang JW, Jagu S, Kirnbauer R, Roden RB.

PLoS One. 2014 May 9;9(5):e97232. doi: 10.1371/journal.pone.0097232. eCollection 2014.

35.

Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.

Kalnin K, Tibbitts T, Yan Y, Stegalkina S, Shen L, Costa V, Sabharwal R, Anderson SF, Day PM, Christensen N, Schiller JT, Jagu S, Roden RB, Almond J, Kleanthous H.

Vaccine. 2014 Jun 12;32(28):3540-7. doi: 10.1016/j.vaccine.2014.04.032. Epub 2014 Apr 26.

36.

Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.

Coughlin K, Anchoori R, Iizuka Y, Meints J, MacNeill L, Vogel RI, Orlowski RZ, Lee MK, Roden RB, Bazzaro M.

Clin Cancer Res. 2014 Jun 15;20(12):3174-86. doi: 10.1158/1078-0432.CCR-13-2658. Epub 2014 Apr 11.

37.

Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.

Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, McEachron TA, Salhia B, Prat J, D'Angelo E, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RB, Cunliffe HE, Huntsman DG, Trent JM.

Nat Genet. 2014 May;46(5):427-9. doi: 10.1038/ng.2928. Epub 2014 Mar 23.

38.

Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells.

Peng S, Song L, Knoff J, Wang JW, Chang YN, Hannaman D, Wu TC, Alvarez RD, Roden RB, Hung CF.

Cell Biosci. 2014 Mar 4;4(1):11. doi: 10.1186/2045-3701-4-11.

39.

Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.

Wang JW, Jagu S, Kwak K, Wang C, Peng S, Kirnbauer R, Roden RB.

Virology. 2014 Jan 20;449:304-16. doi: 10.1016/j.virol.2013.10.038. Epub 2013 Dec 20.

40.

A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.

Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T, Orlowski RZ, Matsui W, Zhao M, Rudek MA, Hung CF, Chen X, Walters KJ, Roden RB.

Cancer Cell. 2013 Dec 9;24(6):791-805. doi: 10.1016/j.ccr.2013.11.001.

41.

Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors.

Wu CY, Yang LH, Yang HY, Knoff J, Peng S, Lin YH, Wang C, Alvarez RD, Pai SI, Roden RB, Hung CF, Wu TC.

Clin Cancer Res. 2014 Feb 1;20(3):644-57. doi: 10.1158/1078-0432.CCR-13-1334. Epub 2013 Dec 3.

42.

Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.

Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RBS, Kirnbauer R.

J Invest Dermatol. 2013 Dec;133(12):2706-2713. doi: 10.1038/jid.2013.253. Epub 2013 May 10.

43.

L2, the minor capsid protein of papillomavirus.

Wang JW, Roden RB.

Virology. 2013 Oct;445(1-2):175-86. doi: 10.1016/j.virol.2013.04.017. Epub 2013 May 17. Review.

44.

Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.

Kwak K, Jiang R, Jagu S, Wang JW, Wang C, Christensen ND, Roden RB.

PLoS One. 2013;8(3):e60507. doi: 10.1371/journal.pone.0060507. Epub 2013 Mar 25.

45.

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.

Jagu S, Kwak K, Schiller JT, Lowy DR, Kleanthous H, Kalnin K, Wang C, Wang HK, Chow LT, Huh WK, Jaganathan KS, Chivukula SV, Roden RB.

J Virol. 2013 Jun;87(11):6127-36. doi: 10.1128/JVI.03218-12. Epub 2013 Mar 27.

46.

Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity.

Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW, Alvarez RD, Roden RB, Pardoll D, Hung CF, Wu TC.

Cancer Res. 2013 Apr 15;73(8):2493-504. doi: 10.1158/0008-5472.CAN-12-4241. Epub 2013 Feb 15.

47.

Virus-like particles for the prevention of human papillomavirus-associated malignancies.

Wang JW, Roden RB.

Expert Rev Vaccines. 2013 Feb;12(2):129-41. doi: 10.1586/erv.12.151. Review.

48.

Optimization of multimeric human papillomavirus L2 vaccines.

Jagu S, Kwak K, Karanam B, Huh WK, Damotharan V, Chivukula SV, Roden RB.

PLoS One. 2013;8(1):e55538. doi: 10.1371/journal.pone.0055538. Epub 2013 Jan 31.

49.

Personalized chemotherapy profiling using cancer cell lines from selectable mice.

Kamiyama H, Rauenzahn S, Shim JS, Karikari CA, Feldmann G, Hua L, Kamiyama M, Schuler FW, Lin MT, Beaty RM, Karanam B, Liang H, Mullendore ME, Mo G, Hidalgo M, Jaffee E, Hruban RH, Jinnah HA, Roden RB, Jimeno A, Liu JO, Maitra A, Eshleman JR.

Clin Cancer Res. 2013 Mar 1;19(5):1139-46. doi: 10.1158/1078-0432.CCR-12-2127. Epub 2013 Jan 22.

50.

Immunohistochemical detection of human papillomavirus capsid proteins L1 and L2 in squamous intraepithelial lesions: potential utility in diagnosis and management.

Yemelyanova A, Gravitt PE, Ronnett BM, Rositch AF, Ogurtsova A, Seidman J, Roden RB.

Mod Pathol. 2013 Feb;26(2):268-74. doi: 10.1038/modpathol.2012.156. Epub 2012 Sep 21.

Supplemental Content

Loading ...
Support Center